Skip to main content

Orthovisc® / Orthovisc® T Injection Therapy

A trusted hyaluronic acid platform for small‑joint and extremity osteoarthritis

A trusted hyaluronic acid platform for small‑joint and extremity osteoarthritis

Order products
Discuss with Eos Active

With over 20 million injections used worldwide

Orthovisc is a well‑established hyaluronic acid (HA) injection with one of the longest clinical heritages in viscosupplementation. It is recognised for its safety, consistency, and predictable performance.

While Orthovisc is historically known for multi‑injection knee protocols, current clinical practice has evolved. Today, Orthovisc and Orthovisc T are commonly positioned as versatile HA options for smaller joints and extremity applications, where control, familiarity, and repeatability matter.

The Technology

Pure, non‑crosslinked hyaluronic acid

Orthovisc is a non‑crosslinked, high‑purity hyaluronic acid derived through bacterial fermentation. Its formulation delivers a naturally optimised molecular weight profile designed to support joint lubrication and synovial function.

Key characteristics include:

  • Non‑animal derived HA
  • Non‑crosslinked structure
  • High biocompatibility within the joint environment
  • Predictable handling and injection characteristics

Orthovisc T offers the same core HA formulation but targets tendonopathies, like tennis elbow. Both Orthovisc and Orthovisc T deliver 30mg of hyaluronan in a 2ml preparation.

Clinical Rationale

Why non‑crosslinked HA still has a role

In smaller joints and extremities, treatment priorities are often different from large, load‑bearing joints. Clinicians frequently value:

  • Familiar HA behaviour within the joint
  • Predictable spread and feel during injection
  • The ability to repeat treatment with confidence
  • A conservative option that supports joint mechanics without additional pharmacological components

Orthovisc’s non‑crosslinked HA structure allows it to integrate naturally within synovial fluid, supporting lubrication and joint movement without altering the joint environment aggressively. A sensible choice where control, safety, and repeatability are key considerations.

Clinical Evidence and Key Data

Built on heritage and global experience

Orthovisc is supported by an extensive clinical history and a large body of published data, primarily in knee osteoarthritis, alongside significant real‑world use across multiple joint types.

Key points:

  • Over 20 million injections used worldwide, reflecting long‑term clinician confidence
  • Extensive clinical trial and post‑market surveillance data supporting safety and tolerability
  • Demonstrated pain reduction and functional improvement in osteoarthritic joints
  • Well‑understood performance profile across repeat treatment cycles

While much of the published trial data focuses on knee OA, Orthovisc’s formulation and handling characteristics have led to its widespread adoption in smaller joints and extremity applications in modern practice.

Full clinical papers and summaries are available within the Eos Active clinical library.

Where Orthovisc® Fits in Clinical Practice

A dependable option for extremity and small‑joint OA

Orthovisc and Orthovisc T are commonly considered for patients with:

  • Symptomatic osteoarthritis affecting smaller joints or extremities, as well as tendon pain
  • A need for a conservative, repeatable HA option
  • Preference for a pure HA without crosslinking or steroid components

In practice, clinicians often use Orthovisc:

  • In hand, wrist, ankle, foot, and other smaller joints
  • Where joint space is limited and injection control is important
  • As part of a stepped non‑operative pathway
  • In patients who may require repeat treatment over time

Supported by Eos Active

Orthovisc’s long clinical heritage is strengthened by how it is supported and positioned within modern practice.

At Eos Active, we support Orthovisc and Orthovisc T as dependable tools within a broader joint‑care strategy, particularly where subtlety and repeatability matter.

Clinical confidence and education

  • Guidance on extremity and small‑joint application of HA injections
  • Support interpreting historic knee‑focused data in a modern clinical context
  • Access to evidence summaries through the Eos clinical library

Patient communication and consent support

  • Clear explanations of what HA does in smaller joints
  • Balanced materials to support informed consent and expectation setting
  • Resources designed for patients who may be new to injection therapy

Practice integration

  • Help positioning Orthovisc within a stepped non‑operative pathway
  • Support aligning HA use with rehabilitation, activity modification, and longer‑term joint care
  • Practical advice for repeat‑treatment planning where appropriate

A partnership approach

  • Direct access to Eos Active for discussion and case‑based support
  • Long‑term focus on safe, ethical, and sustainable use
  • Emphasis on clinical judgement over product‑driven protocols

A proven option, applied thoughtfully

Orthovisc is not new – and that is its strength.

For clinicians managing smaller joints and extremity osteoarthritis, it offers a familiar, trusted HA option backed by decades of use and millions of injections worldwide.

Orthovisc is not the only premium product we can offer you. You can learn more on our products page.

Eos Portfolio

Book a call, get in touch

Discuss with our Managing Director, Jim, to learn more about Orthovisc, and so we know where and how to work best with you.

Eos Active Contact